ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022
A Comprehensive Assessment of
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
Expanded Access to Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrent Prostate Cancer
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Comparison ofFrontiers in oncology · 2024Pooled it
- Pooled it
- Expression of Prostate-Specific Membrane Antigen in Salivary Gland Tumors.Oncology and therapy · 2026Article
- PSMA PET/CT improves precision diagnosis, treatment, and clinical decision-making in prostate cancer.American journal of translational research · 2026Review
- Reply to: Byproducts in the synthesis of [Nature protocols · 2025Article
- Integrating Prostate Specific Membrane Antigen-PET into Clinical Practice for Prostate Cancer.PET clinics · 2025Review
- [EJNMMI reports · 2024Article
- Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Observational
- Evaluation ofAnnals of nuclear medicine · 2024Article
- Application of next-generation imaging in biochemically recurrent prostate cancer.Prostate cancer and prostatic diseases · 2024Review
- Article
- Invited Commentary: Advanced Anatomic and Molecular Imaging in Recurrent Prostate Cancer.Radiographics : a review publication of the Radiological Society of North America, Inc · 2023Article
- Salvage prostate bed plus elective pelvic node radiation without androgen deprivation therapy.Journal of cancer research and clinical oncology · 2023Article
- The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging.Prostate cancer and prostatic diseases · 2023Review
- PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml.European journal of nuclear medicine and molecular imaging · 2023Article
- Detecting and Locating the Site of Local Relapse UsingMolecular imaging and biology · 2023Article
- Can PSMA PET/CT help in dose-tailoring in post-prostatectomy radiotherapy?Frontiers in oncology · 2023Article
- Article
- Best Approaches and Updates for Prostate Cancer Biochemical Recurrence.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2022Review
- The Value of Multimodality PET/CT Imaging in Detecting Prostate Cancer Biochemical Recurrence.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
Abstract
We prospectively investigated the performance of the prostate-specific membrane antigen (PSMA) ligand
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.